{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:50:41Z","timestamp":1790653841102,"version":"4.1.0"},"reference-count":61,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T00:00:00Z","timestamp":1453939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Longevity is increasing and the population of older adults is growing. The biology of aging is conducive to cardiovascular disease (CVD), such that prevalence of coronary artery disease, heart failure, valvular heart disease, arrhythmia and other disorders are increasing as more adults survive into old age.\u00a0 Furthermore, CVD in older adults is distinctive, with management issues predictably complicated by multimorbidity, polypharmacy, frailty and other complexities of care that increase management risks (e.g., bleeding, falls, and rehospitalization) and uncertainty of outcomes.\u00a0 In this review, state-of-the-art advances in heart failure, acute coronary syndromes, transcatheter aortic valve replacement, atrial fibrillation, amyloidosis, and CVD prevention are discussed.\u00a0 Conceptual benefits of treatments are considered in relation to the challenges and ambiguities inherent in their application to older patients.<\/ns4:p>","DOI":"10.12688\/f1000research.7088.1","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T05:05:05Z","timestamp":1453957505000},"page":"112","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Improved Cardiovascular Disease Outcomes in Older Adults"],"prefix":"10.12688","volume":"5","author":[{"given":"Daniel E.","family":"Forman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph G.","family":"Brindis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne B.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette K.","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2016,1,28]]},"reference":[{"key":"ref-1","article-title":"An Aging Nation: The older population in the United States","author":"J Ortman","year":"2014"},{"key":"ref-2","article-title":"National Institute of Aging","year":"2015"},{"key":"ref-3","article-title":"International Data Base","year":"2009"},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"1286-99","DOI":"10.1016\/j.jacc.2015.07.048","article-title":"What to Expect From the Evolving Field of Geriatric Cardiology.","volume":"66","author":"S Bell","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"263-71","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.","volume":"62","author":"W Paulus","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"2281-93","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction.","volume":"64","author":"R Mentz","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"309-16","DOI":"10.1016\/j.jacc.2009.07.066","article-title":"Geriatric conditions and subsequent mortality in older patients with heart failure.","volume":"55","author":"S Chaudhry","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"521-31","DOI":"10.1093\/aje\/kwu268","article-title":"Risk factors for falls among seniors: implications of gender.","volume":"181","author":"V Chang","year":"2015","journal-title":"Am J Epidemiol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"993-1004","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"J McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1383-92","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction.","volume":"370","author":"B Pitt","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"174-86","DOI":"10.1093\/europace\/euu296","article-title":"Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations.","volume":"17","author":"S Barra","year":"2015","journal-title":"Europace."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"161-7","DOI":"10.1016\/j.cardfail.2013.12.015","article-title":"Survival in elderly patients supported with continuous flow left ventricular assist device as bridge to transplantation or destination therapy.","volume":"20","author":"A Rosenbaum","year":"2014","journal-title":"J Card Fail."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"286-93","DOI":"10.1161\/CIRCHEARTFAILURE.111.963215","article-title":"Frailty and the selection of patients for destination therapy left ventricular assist device.","volume":"5","author":"K Flint","year":"2012","journal-title":"Circ Heart Fail."},{"key":"ref-14","first-page":"246-93","article-title":"Frailty and he selection of patients for destination therapy for left ventricular assist device.","volume":"5","author":"K Murad","year":"2012","journal-title":"Circ Hrt Fail."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"263-99","DOI":"10.1016\/j.cardfail.2015.02.007","article-title":"Heart failure management in skilled nursing facilities: a scientific statement from the American Heart Association and the Heart Failure Society of America.","volume":"21","author":"C Jurgens","year":"2015","journal-title":"J Card Fail."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"121-34","DOI":"10.1016\/j.cardfail.2013.12.003","article-title":"End-of-life care in patients with heart failure.","volume":"20","author":"D Whellan","year":"2014","journal-title":"J Card Fail."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"981-9","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.","volume":"62","author":"M Lamberts","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"1107-15","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.","volume":"381","author":"W Dewilde","year":"2013","journal-title":"Lancet."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"224-32","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.","volume":"35","author":"J Alexander","year":"2014","journal-title":"Eur Heart J."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"582-90","DOI":"10.1016\/j.amjmed.2014.12.032","article-title":"Cumulative incidence of death and rehospitalization among the elderly in the first year after NSTEMI.","volume":"128","author":"R Lopes","year":"2015","journal-title":"Am J Med."},{"key":"ref-21","doi-asserted-by":"publisher","DOI":"10.1177\/2048872615581502","article-title":"Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.","author":"H White","year":"2015","journal-title":"EEur Heart J Acute Cardiovasc Care."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"2187-98","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients.","volume":"364","author":"C Smith","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"967-8","DOI":"10.1056\/NEJMc1408396","article-title":"Transcatheter aortic-valve replacement with a self-expanding prosthesis.","volume":"371","author":"D Adams","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-24","article-title":"Decision Memo for Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430N)","year":"2015"},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"2149-50","DOI":"10.1001\/jama.2011.1675","article-title":"Rational dispersion for the introduction of transcatheter valve therapy.","volume":"306","author":"M Mack","year":"2011","journal-title":"JAMA."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"380-9","DOI":"10.1016\/j.athoracsur.2011.05.067","article-title":"Transcatheter valve therapy: a professional society overview from the American College of Cardiology Foundation and the Society of Thoracic Surgeons.","volume":"92","author":"D Holmes","year":"2011","journal-title":"Ann Thorac Surg."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1200-54","DOI":"10.1016\/j.jacc.2012.01.001","article-title":"2012 ACCF\/AATS\/SCAI\/STS expert consensus document on transcatheter aortic valve replacement.","volume":"59","author":"D Holmes","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1026-34","DOI":"10.1016\/j.jacc.2013.03.060","article-title":"The STS-ACC transcatheter valve therapy national registry: a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies.","volume":"62","author":"J Carroll","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"2069-77","DOI":"10.1001\/jama.2013.282043","article-title":"Outcomes following transcatheter aortic valve replacement in the United States.","volume":"310","author":"M Mack","year":"2013","journal-title":"JAMA."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1019-28","DOI":"10.1001\/jama.2015.1474","article-title":"Clinical outcomes at 1 year following transcatheter aortic valve replacement.","volume":"313","author":"D Holmes","year":"2015","journal-title":"JAMA."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"e25-146","DOI":"10.1161\/CIRCULATIONAHA.107.187998","article-title":"Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.","volume":"117","author":"W Rosamond","year":"2008","journal-title":"Circulation."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"2071-104","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.","volume":"130","author":"C January","year":"2014","journal-title":"Circulation."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"493-503","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.","volume":"370","author":"J Mant","year":"2007","journal-title":"Lancet."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"824-9","DOI":"10.1161\/CIRCULATIONAHA.110.007864","article-title":"Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation.","volume":"124","author":"D Poli","year":"2011","journal-title":"Circulation."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"2689-96","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.","volume":"115","author":"E Hylek","year":"2007","journal-title":"Circulation."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1139-51","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"S Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"883-91","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"M Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"981-92","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"C Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"2093-104","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"R Giugliano","year":"2013","journal-title":"N Engl J Med."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"194-204","DOI":"10.1161\/CIRCULATIONAHA.114.013267","article-title":"Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis.","volume":"132","author":"M Sharma","year":"2015","journal-title":"Circulation."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"113-22","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.","volume":"2","author":"S Mohammed","year":"2014","journal-title":"JACC Heart Fail."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"2585-94","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"1275-80","DOI":"10.1016\/j.amjmed.2015.05.039","article-title":"Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology.","volume":"128","author":"M Maurer","year":"2015","journal-title":"Am J Med."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"21-9","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans.","volume":"372","author":"C Quarta","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"117-24","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender.","volume":"20","author":"C Rapezzi","year":"2015","journal-title":"Heart Fail Rev."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"195-201","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.","volume":"6","author":"S Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"519-26","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.","volume":"8","author":"M Maurer","year":"2015","journal-title":"Circ Heart Fail."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"56-61","DOI":"10.1002\/clc.22338","article-title":"Statins in the elderly: a patient-focused approach.","volume":"38","author":"K Wilmot","year":"2015","journal-title":"Clin Cardiol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"1361-8","DOI":"10.1016\/j.jacc.2015.01.043","article-title":"Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC\/AHA Guidelines.","volume":"65","author":"S Martin","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"507-20","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).","volume":"311","author":"P James","year":"2014","journal-title":"JAMA."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"2037-114","DOI":"10.1016\/j.jacc.2011.01.008","article-title":"ACCF\/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.","volume":"57","author":"W Aronow","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"219-26","DOI":"10.1016\/j.ijcard.2014.07.067","article-title":"Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication.","volume":"176","author":"M Banach","year":"2014","journal-title":"Int J Cardiol."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"S1-45","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"N Stone","year":"2014","journal-title":"Circulation."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"A1366","DOI":"10.1016\/S0735-1097(15)61366-3","article-title":"Ldl cholesterol reduction in elderly patients with the pcsk9 monoclonal antibody evolocumab (amg 145): a pooled analysis of 1779 patients in phase 2, 3 and open label extension studies.","volume":"65","author":"M Koren","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"1279-90","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet.","volume":"368","author":"R Estruch","year":"2013","journal-title":"N Engl J Med."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"1433-9","DOI":"10.1001\/jama.292.12.1433","article-title":"Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project.","volume":"292","author":"K Knoops","year":"2004","journal-title":"JAMA."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"e89447","DOI":"10.1371\/journal.pone.0089447","article-title":"Potential therapeutic competition in community-living older adults in the U.S.: use of medications that may adversely affect a coexisting condition.","volume":"9","author":"S Lorgunpai","year":"2014","journal-title":"PLoS One."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"1658-62","DOI":"10.1111\/jgs.13534","article-title":"Older Adults' Recognition of Trade-Offs in Healthcare Decision-Making.","volume":"63","author":"S Case","year":"2015","journal-title":"J Am Geriatr Soc."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"747-62","DOI":"10.1016\/j.jacc.2013.09.070","article-title":"Frailty assessment in the cardiovascular care of older adults.","volume":"63","author":"J Afilalo","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"395-410","DOI":"10.1016\/j.berh.2014.07.005","article-title":"Musculoskeletal health, frailty and functional decline.","volume":"28","author":"R Milte","year":"2014","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-015-0106-5","article-title":"'Hearts and minds': association, causation and implication of cognitive impairment in heart failure.","volume":"7","author":"J Cannon","year":"2015","journal-title":"Alzheimers Res Ther."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/5-112\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-112\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-112\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T09:42:04Z","timestamp":1553247724000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/5-112\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,28]]},"references-count":61,"URL":"https:\/\/doi.org\/10.12688\/f1000research.7088.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.7631.r12151","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.7631.r12153","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.7631.r12152","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.7631.r12152","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.7631.r12151","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.7631.r12153","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,28]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/5-112\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.7631.r12151, Joseph Alpert, Department of Medicine, University of Arizona, Tucson, Arizona, USA, 28 Jan 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-112\/v1#referee-response-12151","order":0,"name":"referee-response-12151","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.7631.r12152, Brian Olshansky, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA, 28 Jan 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-112\/v1#referee-response-12152","order":1,"name":"referee-response-12152","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.7631.r12153, Michael Gaziano, Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA, USA, 28 Jan 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-112\/v1#referee-response-12153","order":2,"name":"referee-response-12153","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"Mathew Maurer\u2019s institution, Columbia University Medical Center, receives funding for research and serving on advisory boards and DSMBs from Pfizer Inc., Alnylam Pharmaceuticals Inc., ISIS Pharmaceuticals and Prothena Inc.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}